Top Headlines

Guest article

Pharma consolidation and the downstream impact on CROs

Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).

News in brief

Marina buys Smarticles liposomal delivery system

Marina Biotech has acquired the intellectual property for the Smarticles liposomal-based delivery system from Novosom AG.

ATMI doubles bioprocess tech manufacturing capacity

ATMI completes expansion at US bioprocess tech plant days after citing life science business growth as an important part of its second quarter gains.

Solid diabetes sales drive slight Q3 growth at BD Medical

The medical unit of Becton Dickinson (BD) reported a slight increase in revenues in the third quarter driven by solid sales of diabetes products.

Mylan plans €67m solid-dose packaging plant in Hungary

Mylan hopes new solid-dose packaging plant in Hungary will help it increase market share in Eastern Europe.

Today's headlines across the Pharmaceutical industry

Exclusive interview

Demand for discovery services recovering, says Domainex from Outsourcing-Pharma.com

Demand for drug discovery services is growing again according to Domainex, who predicted that we will see greater pharmaceutical industry reliance on specialist CROs going forward.

News in brief

GSK taps NCCN for cancer drug trials from Outsourcing-Pharma.com

GSK has awarded the National Comprehensive Cancer Network (NCCN) grants worth $4m to support trials involving ofatumumab and pazopanib.

Chiltern grows market share in FY 2010; plans global expansion from Outsourcing-Pharma.com

CRO Chiltern International says market share grew in fiscal 2010, citing strengthened industrial relationships and global expansion as drivers.

Covance op income down as Phase III delays hit margins from Outsourcing-Pharma.com

Covance has recorded a 29 per cent drop in operating income, despite revenue growth, as cost reduction actions and Phase III delays hit margins.

On your radar